Hirte HW - Search Results

1

Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses.

Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM. Elit L, et al. Among authors: hirte hw. Cancer. 2007 Feb 15;109(4):692-702. doi: 10.1002/cncr.22466. Cancer. 2007. PMID: 17238181 Free article. Review.

2

Chemotherapy for recurrent epithelial ovarian cancer previously treated with platinum--a systematic review of the evidence from randomized trials.

Fung MF, Johnston ME, Eisenhauer EA, Elit L, Hirte HW, Rosen B; Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group. Fung MF, et al. Among authors: hirte hw. Eur J Gynaecol Oncol. 2002;23(2):104-10. Eur J Gynaecol Oncol. 2002. PMID: 12013102 Review.

3

Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review.

Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Hirte HW, et al. Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1194-204. doi: 10.1111/j.1525-1438.2007.00900.x. Epub 2007 Jun 1. Int J Gynecol Cancer. 2007. PMID: 17540006 Review.

4

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P. Fung-Kee-Fung M, et al. Among authors: hirte hw. Curr Oncol. 2007 Oct;14(5):195-208. doi: 10.3747/co.2007.148. Curr Oncol. 2007. PMID: 17938703 Free PMC article.

5

Outcomes for systemic therapy in women with ovarian cancer.

Elit L, Chartier C, Oza A, Hirte H, Levine M, Paszat L. Elit L, et al. Gynecol Oncol. 2006 Nov;103(2):554-8. doi: 10.1016/j.ygyno.2006.03.052. Epub 2006 May 24. Gynecol Oncol. 2006. PMID: 16725183

6

Novel strategies for systemic treatment of endometrial cancer.

Elit L, Hirte H. Elit L, et al. Expert Opin Investig Drugs. 2000 Dec;9(12):2831-53. doi: 10.1517/13543784.9.12.2831. Expert Opin Investig Drugs. 2000. PMID: 11093356 Review.

7

Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis.

Lukka H, Hirte H, Fyles A, Thomas G, Elit L, Johnston M, Fung MF, Browman G; Cancer Care Ontario Practice Guidelines Initiative Gynecology Disease Site Group. Lukka H, et al. Clin Oncol (R Coll Radiol). 2002 Jun;14(3):203-12. doi: 10.1053/clon.2002.0076. Clin Oncol (R Coll Radiol). 2002. PMID: 12109823

8

A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.

Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K. Kwon JS, et al. Gynecol Oncol. 2002 Mar;84(3):420-5. doi: 10.1006/gyno.2001.6546. Gynecol Oncol. 2002. PMID: 11855881

9

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Oza AM, et al. Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.

10

Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas.

Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P, Webster S, Laughlin A, Stayner LA, McGill S, Wang L, Zhang WJ, Espinoza-Delgado I, Holleran JL, Egorin MJ, Siu LL. Stathis A, et al. Among authors: hirte hw. Clin Cancer Res. 2011 Mar 15;17(6):1582-90. doi: 10.1158/1078-0432.CCR-10-1893. Epub 2011 Jan 28. Clin Cancer Res. 2011. PMID: 21278245 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

102 results

Search Page